KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Consolidated Net Income (2016 - 2026)

Inovio Pharmaceuticals' Consolidated Net Income history spans 16 years, with the latest figure at -$17.0 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 12.76% to -$17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$84.4 million, a 21.71% increase, with the full-year FY2025 number at -$84.4 million, up 21.71% from a year prior.
  • Consolidated Net Income hit -$17.0 million in Q4 2025 for Inovio Pharmaceuticals, up from -$20.7 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for INO hit a ceiling of -$17.0 million in Q4 2025 and a floor of -$108.5 million in Q2 2022.
  • Historically, Consolidated Net Income has averaged -$45.4 million across 5 years, with a median of -$34.7 million in 2023.
  • Biggest five-year swings in Consolidated Net Income: plummeted 387.46% in 2021 and later surged 67.25% in 2023.
  • Tracing INO's Consolidated Net Income over 5 years: stood at -$106.9 million in 2021, then soared by 49.07% to -$54.5 million in 2022, then soared by 54.09% to -$25.0 million in 2023, then grew by 21.94% to -$19.5 million in 2024, then grew by 12.76% to -$17.0 million in 2025.
  • Business Quant data shows Consolidated Net Income for INO at -$17.0 million in Q4 2025, -$20.7 million in Q3 2025, and -$22.5 million in Q2 2025.